Juan Jaen Sells 31,823 Shares of Arcus Biosciences (NYSE:RCUS) Stock

Arcus Biosciences, Inc. (NYSE:RCUS) President Juan Jaen sold 31,823 shares of the business’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $21.41, for a total value of $681,330.43. Following the transaction, the president owned 922,240 shares of the company’s stock, valued at approximately $19,745,158.40. The trade was a 3.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Arcus Biosciences Trading Down 7.8%

RCUS opened at $21.39 on Friday. Arcus Biosciences, Inc. has a 12 month low of $6.50 and a 12 month high of $26.40. The stock has a fifty day moving average price of $22.57 and a 200-day moving average price of $15.45. The company has a current ratio of 3.65, a quick ratio of 3.65 and a debt-to-equity ratio of 0.22. The firm has a market cap of $2.31 billion, a price-to-earnings ratio of -6.22 and a beta of 0.77.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings data on Tuesday, October 28th. The company reported ($1.27) EPS for the quarter, beating the consensus estimate of ($1.33) by $0.06. The business had revenue of $26.00 million during the quarter, compared to analysts’ expectations of $19.89 million. Arcus Biosciences had a negative net margin of 136.40% and a negative return on equity of 68.17%. The business’s quarterly revenue was down 45.8% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.00) EPS. As a group, equities research analysts anticipate that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on RCUS shares. Wedbush set a $35.00 price target on shares of Arcus Biosciences and gave the company an “outperform” rating in a research note on Wednesday, October 29th. HC Wainwright increased their target price on shares of Arcus Biosciences from $28.00 to $32.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. Wells Fargo & Company raised their price objective on shares of Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a research report on Monday, October 20th. UBS Group restated a “buy” rating on shares of Arcus Biosciences in a research report on Monday, December 15th. Finally, Wall Street Zen upgraded shares of Arcus Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, December 14th. Seven investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $28.67.

Institutional Trading of Arcus Biosciences

A number of institutional investors have recently made changes to their positions in the stock. GAMMA Investing LLC grew its position in Arcus Biosciences by 59.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,748 shares of the company’s stock worth $37,000 after purchasing an additional 1,021 shares in the last quarter. SBI Securities Co. Ltd. increased its holdings in Arcus Biosciences by 13,547.6% during the 3rd quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company’s stock valued at $39,000 after purchasing an additional 2,845 shares in the last quarter. CWM LLC lifted its stake in shares of Arcus Biosciences by 233.6% during the second quarter. CWM LLC now owns 5,441 shares of the company’s stock valued at $44,000 after acquiring an additional 3,810 shares during the period. Ameritas Investment Partners Inc. increased its holdings in Arcus Biosciences by 34.3% in the second quarter. Ameritas Investment Partners Inc. now owns 7,038 shares of the company’s stock valued at $57,000 after purchasing an additional 1,796 shares during the last quarter. Finally, PNC Financial Services Group Inc. grew its position in shares of Arcus Biosciences by 440.3% in the 2nd quarter. PNC Financial Services Group Inc. now owns 7,597 shares of the company’s stock valued at $62,000 after purchasing an additional 6,191 shares during the period. 92.89% of the stock is owned by institutional investors and hedge funds.

Arcus Biosciences Company Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.